{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:50:29Z","timestamp":1753890629339,"version":"3.41.2"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The acute myocardial infarction (AMI) is a prevalent and severe cardiovascular disease, characterized by its sudden onset, high mortality rate, and unfavorable prognosis. The presence of type 2 diabetes not only signifies a chronic metabolic disorder, but also serves as a catalyst for various cardiovascular and cerebrovascular ailments such as coronary heart disease and stroke. Xining is situated in a region of middle to high altitude and due to its unique geographical environment, coupled with the population's limited health awareness, unequal medical standards and other factors, there remain some AMI patients who are difficult to diagnose early on. The objective of this study is to investigate the efficacy and prognosis of dapagliflozin in patients with acute myocardial infarction complicated by type 2 diabetes in the Xining region.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>analysis on January 1, 2018 to January 1, 2020, in Qinghai province people's hospital of cardiovascular internal medicine hospital treatment of 245 cases of acute myocardial infarction combined the clinical data of patients with type 2 diabetes. The patients were divided into dapagliflozin group and control group according to whether they took dapagliflozin during hospitalization. The basic data, laboratory examination indicators and long-term prognosis of the two groups were observed. Follow-up deadline is December 31, 2023, at the end of follow-up, including the primary endpoint and the secondary endpoint.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>245 patients were included in this study, age 34\u201394, the average age (61\u201311), 200 cases (81.63%) of men, women, 45 cases (18.37%), dapagliflozin group of men 92 cases (77.97%) and control group, 108 cases (85.04%). Two groups of patients' age, gender, diabetes duration, merge disease, echocardiogram and blood biochemical indexes, had no statistical difference (<jats:italic>P<\/jats:italic>\u2009&amp;gt;\u20090.05). There were no significant differences in the number of coronary artery lesions, treatment regimens, cardiovascular and hypoglycemic drugs between the two groups (<jats:italic>P<\/jats:italic>\u2009&amp;gt;\u20090.05). However, up to dapagliflozin group of patients after discharge significantly lower than the control group, the incidence of cardiovascular adverse events at dapagliflozin group of 4 cases of heart failure and cardiovascular death in 1 case and control group in heart failure 13 cases, 10 cases of cardiovascular death, cerebral hemorrhage 2 cases died. KaplanMeier survival analysis showed that the primary endpoint of survival was significantly higher in the dapagliflozin group than in the control group (<jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.05). In addition, the overall survival rate of the dapagliflozin group was significantly higher than that of the control group, and the difference was statistically significant (<jats:italic>P<\/jats:italic>\u2009&amp;lt;\u20090.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Dapagliflozin is safe and reliable in the treatment of patients with acute myocardial infarction and type 2 diabetes, and can effectively reduce the incidence of cardiovascular events and improve the overall survival rate of patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2025.1500978","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T07:29:36Z","timestamp":1739345376000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and prognosis of dapagliflozin in the treatment of patients with acute myocardial infarction complicated with type 2 diabetes in Xining area"],"prefix":"10.3389","volume":"12","author":[{"given":"Jinping","family":"Chai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanmin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.3969\/j.issn.1009-0126.2022.06.012","article-title":"Study on the clinical features and long-term prognosis of patients with coronary microcirculation dysfunction after acute myocardial infarction in the elderly","volume":"24","author":"Wang","year":"2022","journal-title":"Chin J Geriatr Cardiovasc Cerebrovasc Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"450","DOI":"10.3969\/j.issn.1000-3614.2020.05.006","article-title":"Establishment of risk factors and prediction model for perioperative myocardial infarction in percutaneous coronary intervention","volume":"35","author":"Zhou","year":"2020","journal-title":"Chin Circ J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3969\/j.issn.1009-0126.2017.05.023","article-title":"Advances in genetic research on early onset myocardial infarction","volume":"19","author":"Cui","year":"2017","journal-title":"Chin J Geriatr Cardiovasc Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.59249\/LSWK8578","article-title":"Arrhythmias after acute myocardial infarction","volume":"96","author":"Frampton","year":"2023","journal-title":"Yale J Biol Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s15006-019-0223-3","article-title":"Hat der patient einen herzinfarkt? [Diagnosis and initial management of acute myocardial infarction]","volume":"161","author":"Zeymer","year":"2019","journal-title":"MMW Fortschr Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrendo.2017.151","article-title":"Global aetiology and epidemiology of type 2 diabetes mellitus and its complications","volume":"14","author":"Zheng","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1111\/jdi.13756","article-title":"Non-alcoholic fatty liver disease and type 2 diabetes: an update","volume":"13","author":"Lee","year":"2022","journal-title":"J Diabetes Investig"},{"key":"B8","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ahj.2023.08.008","article-title":"Rationale and design of the DAPA-MI trial: dapagliflozin in patients without diabetes mellitus with acute myocardial infarction","volume":"266","author":"James","year":"2023","journal-title":"Am Heart J"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1161\/CIRCULATIONAHA.119.039996","article-title":"Dapagliflozin and cardiovascular outcomes in patients with type 2 diabetes Mellitus and previous myocardial infarction","volume":"139","author":"Furtado","year":"2019","journal-title":"Circulation"},{"key":"B10","doi-asserted-by":"publisher","first-page":"437","DOI":"10.16680\/j.1671-3826.2020.04.29","article-title":"The effect of dapagliflozin on insulin resistance index in patients with type 2 diabetes receiving short-term intensive insulin pump therapy","volume":"48","author":"Han","year":"2020","journal-title":"J Clin Mil Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S2213-8587(21)00113-3","article-title":"Treatment of type 2 diabetes: challenges, hopes, and anticipated successes","volume":"9","author":"Nauck","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12916-023-02781-2","article-title":"SGLT-2 inhibitors and in-stent restenosis-related events after acute myocardial infarction: an observational study in patients with type 2 diabetes","volume":"21","author":"Marfella","year":"2023","journal-title":"BMC Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3969\/j.issn.1007-5410.2022.02.002","article-title":"Effect of daglizin on prognosis of patients with acute myocardial infarction complicated with type 2 diabetes","volume":"27","author":"Huo","year":"2022","journal-title":"Chin J Cardiol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e618","DOI":"10.1161\/CIR.0000000000000617","article-title":"Fourth universal definition of myocardial infarction(2018)","volume":"138","author":"Thygesen","year":"2018","journal-title":"Circulation"},{"key":"B15","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3760\/cma.j.cn115791-20210221-00095","article-title":"Chinese guidelines for the prevention and treatment of type 2 diabetes (2020 edition)","volume":"37","year":"2021","journal-title":"Chin J Endocrinol Metab"},{"key":"B16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3969\/j.issn.1007-3809.2012.03.009","article-title":"Preliminary analysis of the composition ratio of acute myocardial infarction in Xining area in the past 10 years (2002\u20132012)","volume":"22","author":"Liu","year":"2012","journal-title":"J Plateau Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"609","DOI":"10.3969\/j.issn.1005-2194.2003.10.016","article-title":"Analysis of the application of selective coronary angiography and interventional treatment in high altitude conditions","volume":"23","author":"Li","year":"2003","journal-title":"Chin J Pract Int Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.3969\/j.issn.1674-4055.2021.10.33","article-title":"The effect of high altitude environment on cardiovascular system physiological indicators and diseases","volume":"13","author":"Fan","year":"2021","journal-title":"Chin J Evid Based Cardiovasc Med"},{"key":"B19","first-page":"39","article-title":"Effect of reperfusion therapy strategy on prognosis of acute myocardial infarction with ST segment elevation in Xining area","volume":"26","author":"Li","year":"2016","journal-title":"J High Altitude Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3969\/j.issn.1007-3809.2013.04.006","article-title":"Study on common risk factors and coronary artery lesion severity in Tibetan and Han patients with coronary heart disease in Xining area","volume":"23","author":"Shang","year":"2013","journal-title":"J Plateau Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"535","DOI":"10.3760\/j.issn.1673-4777.2022.04.014","article-title":"Analysis of type 2 diabetes incidence among different types of obese patients in Xining area","volume":"17","author":"Jiang","year":"2022","journal-title":"Chin Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/dom.13477","article-title":"Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes","volume":"21","author":"Dawwas","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"B23","doi-asserted-by":"publisher","first-page":"106597","DOI":"10.1016\/j.phrs.2022.106597","article-title":"Outcomes in diabetic patients treated with SGLT2-inhibitors with acute myocardial infarction undergoing PCI: the SGLT2-I AMI PROTECT registry","volume":"187","author":"Paolisso","year":"2023","journal-title":"Pharmacol Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.3969\/j.issn.1671-8348.2019.16.041","article-title":"Clinical evaluation of dapagliflozin in patients with type 2 diabetes and heart failure in China: a meta-analysis","volume":"48","author":"Yang","year":"2019","journal-title":"Chongqing Med J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"493","DOI":"10.12102\/j.issn.1672-1349.2022.08.034","article-title":"The effect of dapagliflozin on cardiac function in patients with acute myocardial infarction and diabetes: a study based on the data from the DAPA-CKD trial","volume":"20","author":"Chen","year":"2022","journal-title":"J Integr Cardiovasc Cerebrovasc Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12933-020-01071-y","article-title":"SGLT2i: beyond the glucose-lowering effect","volume":"19","author":"Ni","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.3969\/j.issn.1674-4055.2023.09.12","article-title":"The effect of dapagliflozin on cardiac function and left ventricular remodeling in patients with acute myocardial infarction and type 2 diabetes","volume":"15","author":"Lin","year":"2023","journal-title":"Chin Evid Based Cardiovasc Med J"},{"key":"B29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.3969\/j.issn.1007-5410.2022.02.002","article-title":"Effect of dapagliflozin on prognosis of patients with acute myocardial infarction and type 2 diabetes mellitus","volume":"27","author":"Huo","year":"2022","journal-title":"Chin J Cardiovasc Dis"},{"key":"B30","doi-asserted-by":"publisher","first-page":"6","DOI":"10.14164\/j.cnki.cn11-5581\/r.2023.06.002","article-title":"The effect of dapagliflozin on the incidence of major cardiovascular adverse events in patients with acute myocardial infarction and type 2 diabetes","volume":"17","author":"Li","year":"2023","journal-title":"Chin J Modern Pharmacy"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.11855\/j.issn.0577-7402.2162.2023.0523","article-title":"The effect of dapagliflozin on cardiac function and MACE in older patients with acute myocardial infarction and heart failure","volume":"48","author":"Liu","year":"2023","journal-title":"J PLA Med J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.3969\/j.issn.1004-0412.2023.11.036","article-title":"Glycemic indicators and adverse reactions of dapagliflozin and saxagliptin in the treatment of type 2 diabetes","volume":"44","author":"Zheng","year":"2023","journal-title":"Jilin Med J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"292","DOI":"10.23736\/S2724-5683.23.06478-5","article-title":"Effects of dapagliflozin on cardiac function and short-term prognosis of patients with both acute myocardial infarction and type 2 diabetes mellitus","volume":"72","author":"Zhou","year":"2024","journal-title":"Minerva Cardiol Angiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12933-023-01911-7","article-title":"Comparative cardiovascular outcomes in type 2 diabetes patients taking dapagliflozin versus empagliflozin: a nationwide population-based cohort study","volume":"22","author":"Lim","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1177\/02676591221127924","article-title":"A study of the efficacy of sacubitril\/valsartan plus dapagliflozin combination treatment in pulmonary arterial hypertension due to left heart disease","volume":"38","author":"Ge","year":"2023","journal-title":"Perfusion"},{"key":"B36","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","article-title":"SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Puckrin","year":"2018","journal-title":"Acta Diabetol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1500978\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T07:29:56Z","timestamp":1739345396000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1500978\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":36,"alternative-id":["10.3389\/fcvm.2025.1500978"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1500978","relation":{},"ISSN":["2297-055X"],"issn-type":[{"type":"electronic","value":"2297-055X"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"article-number":"1500978"}}